glp-1 market size 2024 Receptor Agonist Valued at USD 62.86 Billion in 2025, Set to Grow at 17.5% CAGR Through 2034 GLP-1 Agonists Market Report 2025-2033,

M.HoltR

Although these drugs would make Medicare beneficiaries healthy, preventing heart attacks, strokes, and kidney failure, the net impact would be higher medical costs

This prevents the stomach from feeling overly full, which can trigger nausea

Many complaints describe symptoms that go beyond expected transient nauseasuch as recurring vomiting, delayed gastric emptying, and episodes of severe stomach painwhich is part of why this litigation is unfolding as a coordinated proceeding

McCall shares insights from extensive data collection, suggesting that specific lab markers can predict which patients are likely to maintain weight loss after stopping the medication